Bicara Therapeutics Inc. (BCAX) insider trading.
In Q3 2026, insiders at Bicara Therapeutics Inc. reported 21 non-derivative transactions on 13 Forms 3, 4 and 5: 0 open-market purchases and 14 sales worth $3.5M.
- Transactions
- 21
- Purchases (P)
- 0
- Sales (S)
- 14
- Net shares, P minus S
- -125,500
- Insiders
- 3
- Last filed
- 2026-09-10
Insiders
| Insider | Relationship | Transactions | Buys | Sales |
|---|---|---|---|---|
| Cohlhepp Ryan | Director, Officer · President, COO & Interim CEO | 10 | 0 | 7 |
| Hyep Ivan | Officer · Chief Financial Officer | 6 | 0 | 4 |
| Mazumdar Claire | Director, Officer · Chief Executive Officer | 5 | 0 | 3 |
Transactions
| Date | Insider | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-08 | Cohlhepp Ryan | S (D) | 3,442 | $23.43 | 181,641 | Form 4 |
| 2026-09-08 | Cohlhepp Ryan | S (D) | 14,058 | $22.77 | 185,083 | Form 4 |
| 2026-09-08 | Cohlhepp Ryan | M (A) | 17,500 | $3.79 | 199,141 | Form 4 |
| 2026-08-10 | Cohlhepp Ryan | M (A) | 18,750 | $3.79 | 200,391 | Form 4 |
| 2026-08-10 | Cohlhepp Ryan | S (D) | 18,750 | $27.98 | 181,641 | Form 4 |
| 2026-08-10 | Mazumdar Claire | S (D) | 10,000 | $27.98 | 362,152 | Form 4 |
| 2026-08-10 | Mazumdar Claire | M (A) | 10,000 | $3.79 | 372,152 | Form 4 |
| 2026-08-10 | Hyep Ivan | M (A) | 12,500 | $3.79 | 142,355 | Form 4 |
| 2026-08-10 | Hyep Ivan | S (D) | 12,500 | $27.97 | 129,855 | Form 4 |
| 2026-07-10 | Mazumdar Claire | M (A) | 10,000 | $3.79 | 372,152 | Form 4 |
| 2026-07-10 | Mazumdar Claire | S (D) | 9,972 | $28.42 | 362,180 | Form 4 |
| 2026-07-10 | Mazumdar Claire | S (D) | 28 | $29.68 | 362,152 | Form 4 |
| 2026-07-09 | Cohlhepp Ryan | S (D) | 536 | $29 | 181,641 | Form 4 |
| 2026-07-08 | Hyep Ivan | S (D) | 830 | $30.31 | 129,855 | Form 4 |
| 2026-07-08 | Hyep Ivan | M (A) | 12,500 | $3.79 | 157,855 | Form 4 |
| 2026-07-08 | Hyep Ivan | S (D) | 22,757 | $28.6 | 135,098 | Form 4 |
| 2026-07-08 | Hyep Ivan | S (D) | 4,413 | $29.82 | 130,685 | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | M (A) | 18,750 | $3.79 | 210,391 | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | S (D) | 22,833 | $28.76 | 187,558 | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | S (D) | 1,075 | $30.35 | 182,177 | Form 4 |
| 2026-07-08 | Cohlhepp Ryan | S (D) | 4,306 | $29.8 | 183,252 | Form 4 |
Transaction codes in this quarter
Get BCAX insider transactions through the API
curl "https://sec-api.dev/api/v1/insider-transactions?period=2026q3&cik=2023658&limit=100" \
-H "Authorization: Bearer $SEC_API_KEY"Insider trading API guide · BCAX company page · Bicara Therapeutics Inc. on SEC.gov
Questions
Are insiders buying or selling Bicara Therapeutics Inc. (BCAX)?
In Q3 2026, insiders at Bicara Therapeutics Inc. reported 21 non-derivative transactions on 13 Forms 3, 4 and 5: 0 open-market purchases and 14 sales worth $3.5M. Grants, tax withholding and option exercises are counted as transactions but are not purchases or sales.
Where do these Bicara Therapeutics Inc. insider trades come from?
From the SEC Insider Transactions Data Sets for Q3 2026, which republish the Forms 3, 4 and 5 filed on EDGAR. Each row links to its filing on SEC.gov.
Plain-text version for agents and LLMs: /insider-trading/bcax.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.